Eli Lilly (LLY) has been actively progressing its pharmaceutical offerings and forging new alliances, as recent product ...

Eli Lilly (LLY) reached $762.95 at the closing of the latest trading day, reflecting a -5.59% change compared to its last close.

Novo Nordisk faces slowing demand, rising competition, and CEO transition. Learn about challenges impacting its growth and ...

Danish drugmaker Novo Nordisk's stock was down nearly 20% in premarket trading Tuesday morning after the company cut its ...

IXJ offers global healthcare exposure, capturing demographic shifts and innovation trends beyond U.S.-centric ETFs. Read why ...

Eli Lilly's stock took a noticeable dip following a guidance update from rival Novo Nordisk. Investors reacted sharply as ...

Novo Nordisk's market value plummeted by $70 billion following a profit warning and the appointment of Maziar Mike Doustdar as the new CEO. The company slashed its 2025 sales growth outlook due to ...

CEO-to-be Maziar Mike Doustdar will need to stem the company’s tumbling share price as market pressures intensify.

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

Novo Nordisk shares plunged more than 20% on the 29th (local time) in New York and Denmark on the 29th (local time) due to the announcement of a slowdown in sales growth of the obesity drug "Wegovy".

(Reuters) -Investors and analysts say they expect Eli Lilly to report stronger quarterly sales and profit next week than ...

Source: Bloomberg, data from to 31 March 2025 to 30 June 2025. Returns are for the MSCI All Country World Index (ACWI) and its 11 sectors. The MSCI ACWI Index captures large- and mid-cap ...